Odd Terje Brustugun1, Asma Malik Khattak2, Anette Kjoshagen Trømborg2, Marzieh Beigi2, Klaus Beiske2, Marius Lund-Iversen2, Åslaug Helland3. 1. Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway. Electronic address: otr@ous-hf.no. 2. Department of Pathology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway. 3. Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Abstract
OBJECTIVES: Targeted therapies in non-small cell lung cancer (NSCLC) now also include inhibitors against mutated BRAF. We present clinicopathological characteristics of nearly one thousand unselected NSCLC patients tested for the targetable V600E/K BRAF-mutation. MATERIAL AND METHODS: NSCLC routinely tested for EGFR-mutations at Oslo University Hospital in the period February 2011-July 2013 were tested for V600E/K BRAF-mutations using a PCR-based method. RESULTS: We found a BRAF-mutation frequency of 1.7% in the total cohort of 979 patients, and 2.3% among 646 adenocarcinomas. One of the BRAF-positive samples was also KRAS-mutated, and one had an ALK-translocation. None of 231 squamous cell carcinomas were BRAF-mutated. The proportion of never-smokers among BRAF-positives was high (29%). CONCLUSION: BRAF-mutation analysis should be part of the subtyping of non-squamous NSCLC.
OBJECTIVES: Targeted therapies in non-small cell lung cancer (NSCLC) now also include inhibitors against mutated BRAF. We present clinicopathological characteristics of nearly one thousand unselected NSCLCpatients tested for the targetable V600E/KBRAF-mutation. MATERIAL AND METHODS:NSCLC routinely tested for EGFR-mutations at Oslo University Hospital in the period February 2011-July 2013 were tested for V600E/KBRAF-mutations using a PCR-based method. RESULTS: We found a BRAF-mutation frequency of 1.7% in the total cohort of 979 patients, and 2.3% among 646 adenocarcinomas. One of the BRAF-positive samples was also KRAS-mutated, and one had an ALK-translocation. None of 231 squamous cell carcinomas were BRAF-mutated. The proportion of never-smokers among BRAF-positives was high (29%). CONCLUSION:BRAF-mutation analysis should be part of the subtyping of non-squamous NSCLC.
Authors: J B Auliac; S Bayle; A Vergnenegre; H Le Caer; L Falchero; R Gervais; H Doubre; F Vinas; B Marin; C Chouaid Journal: Curr Oncol Date: 2018-10-31 Impact factor: 3.677
Authors: Yang Yang; Yi Meng; Hang Zhang; Xiaoyan Shen; Rutian Li; Lixia Yu; Baorui Liu; Lifeng Wang Journal: Oncol Lett Date: 2017-12-19 Impact factor: 2.967
Authors: Nathaniel J Myall; Solomon Henry; Douglas Wood; Joel W Neal; Summer S Han; Sukhmani K Padda; Heather A Wakelee Journal: Clin Lung Cancer Date: 2018-10-23 Impact factor: 4.785
Authors: F Oezkan; Am Khan; P Zarogoulidis; W Hohenforst-Schmidt; D Theegarten; K Yasufuku; T Nakajima; L Freitag; K Darwiche Journal: Onco Targets Ther Date: 2014-11-10 Impact factor: 4.147
Authors: Y U Dong; Weihong Ren; Jun Qi; B O Jin; Ying Li; Huiqing Tao; Ren Xu; Yanqing Li; Qinxian Zhang; Baohui Han Journal: Oncol Lett Date: 2016-02-17 Impact factor: 2.967